文献速递糖尿病

1型糖尿病多次每日胰岛素注射患者中HbA1c与低血糖时间在CGM和SMBG中的关联:GOLD-4随机临床试验

The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4).
PubMed 文献 · Diabetes Care · 2020-07-08

GOLD随机交叉试验纳入161例多次每日胰岛素注射的1型糖尿病患者,随机接受CGM或SMBG治疗并随访16个月。研究发现,在CGM和SMBG中,低血糖时间均随平均HbA1c和平均血糖降低而显著增加;在较广的HbA1c范围内,CGM的低血糖时间显著少于SMBG,但两种监测方式下同时达到低血糖时间和HbA1c目标均具有挑战性。

要点

  • 在CGM和SMBG中,低血糖时间(<3.9 mmol/L和<3.0 mmol/L)均随平均HbA1c和平均血糖降低而显著增加。
  • CGM期间HbA1c<7.5%的个体中,24例(57.1%)低血糖<3.0 mmol/L时间<1.0%,23例(54.8%)低血糖<3.9 mmol/L时间<4.0%。
  • 平均血糖8 mmol/L时,SMBG较CGM的低血糖<3.9 mmol/L时间多4.9%单位,<3.0 mmol/L时间多2.8%单位。

核心结论

  • 对于多次每日胰岛素注射的1型糖尿病患者,无论使用CGM还是SMBG,同时达到当前低血糖时间目标和HbA1c目标均具有挑战性;但在较广的HbA1c范围内,CGM的低血糖时间显著少于SMBG,且CGM对于MDI治疗患者有机会接近低血糖目标至关重要。

研究设计与样本

  • GOLD随机交叉试验纳入161例接受多次每日胰岛素注射治疗的1型糖尿病患者,随机分配至CGM或SMBG常规治疗,评估16个月。

主要发现

  • 在CGM和常规治疗中,低血糖时间(<3.9 mmol/L和<3.0 mmol/L)均随平均HbA1c和平均血糖水平降低而显著增加。
  • CGM期间,HbA1c<7.5%(<58 mmol/mol)的个体中,24例(57.1%)低血糖<3.0 mmol/L时间<1.0%,23例(54.8%)低血糖<3.9 mmol/L时间<4.0%。
  • CGM期间,平均HbA1c为7.0%(52 mmol/mol)的个体低血糖<3.9 mmol/L的平均时间估计为5.4%,<3.0 mmol/L为1.5%;SMBG期间相应值分别为9.2%和3.5%。
  • 平均血糖水平为8 mmol/L的个体,SMBG期间较CGM期间低血糖<3.9 mmol/L时间多4.9%单位,<3.0 mmol/L时间多2.8%单位。

关键数值与推荐

  • 近期指南推荐1型糖尿病患者每日血糖<3.9 mmol/L(<70 mg/dL)的时间应<4.0%,每日血糖<3.0 mmol/L(<54 mg/dL)的时间应<1.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: According to recent guidelines, individuals with type 1 diabetes should spend <4.0% of time per day with glucose levels <3.9 mmol/L (<70 mg/dL) and <1.0% per day with glucose levels <3.0 mmol/L (<54 mg/dL). RESEARCH DESIGN AND METHODS: In the GOLD randomized crossover trial, 161 individuals with type 1 diabetes treated with multiple daily insulin injections (MDI) were randomized to continuous glucose monitoring (CGM) or conventional therapy with self-monitoring of blood glucose (SMBG) and evaluated over 16 months. We estimated the association between time spent in hypoglycemia and various mean glucose and HbA1c levels. RESULTS: Time spent in hypoglycemia (<3.9 mmol/L and <3.0 mmol/L) increased significantly with lower mean HbA1c and mean glucose levels during both CGM and conventional therapy. During CGM, 24 (57.1%) individuals with HbA1c <7.5% (<58 mmol/mol) had <1.0% time spent in hypoglycemia <3.0 mmol/L and 23 (54.8%) had <4.0% time spent in hypoglycemia <3.9 mmol/L. During CGM, mean time spent in hypoglycemia for individuals with mean HbA1c 7.0% (52 mmol/mol) was estimated to be 5.4% for <3.9 mmol/L and 1.5% for <3.0 mmol/L. The corresponding values during SMBG were 9.2% and 3.5%, respectively. Individuals with mean glucose levels of 8 mmol/L spent 4.9% units more time with glucose levels <3.9 mmol/L and 2.8% units more time <3.0 mmol/L during SMBG compared with CGM. CONCLUSIONS: Reaching current targets for time in hypoglycemia while at the same time reaching HbA1c targets is challenging for patients with type 1 diabetes treated with MDI both with CGM and SMBG monitoring. However, CGM is associated with considerably less time in hypoglycemia than SMBG at a broad range of HbA1c levels and is crucial for patients with MDI treatment if they are to have a chance to approach hypoglycemia targets.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Seyed Ahmadi S, Westman K, Pivodic A, et al. The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). Diabetes Care. 2020. PMID: 32641374. doi:10.2337/dc19-2606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。